Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126365471 | 12636547 | 1 | I | 20160521 | 20160801 | 20160809 | 20160809 | EXP | FR-ASTRAZENECA-2016SE84968 | ASTRAZENECA | 25183.00 | DY | F | Y | 56.00000 | KG | 20160809 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126365471 | 12636547 | 1 | PS | INEXIUM | ESOMEPRAZOLE | 1 | Oral | Y | 21153 | 20 | MG | QD | |||||||
| 126365471 | 12636547 | 2 | SS | VIDAZA | AZACITIDINE | 1 | Subcutaneous | 0 | 56 | MG | BID | ||||||||
| 126365471 | 12636547 | 3 | SS | ZAMUDOL SR | TRAMADOL HYDROCHLORIDE | 1 | Oral | Y | 0 | 1 | DF | BID | |||||||
| 126365471 | 12636547 | 4 | SS | OROZAMUDOL | TRAMADOL | 1 | Oral | 1 TO 3 DF PER DAY | Y | 0 | |||||||||
| 126365471 | 12636547 | 5 | SS | IMOVANE | ZOPICLONE | 1 | Oral | Y | 0 | 7.5 | MG | QD | |||||||
| 126365471 | 12636547 | 6 | SS | PIPERACILLIN, TAZOBACTAM | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | Intravenous (not otherwise specified) | U | U | 0 | 4 | G | TID | ||||||
| 126365471 | 12636547 | 7 | C | BISOPROLOL | BISOPROLOL | 1 | Oral | 0 | 2.5 | MG | QD | ||||||||
| 126365471 | 12636547 | 8 | C | DUPHALAC | LACTULOSE | 1 | Oral | 0 | |||||||||||
| 126365471 | 12636547 | 9 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 126365471 | 12636547 | 10 | C | PERFALGAN | ACETAMINOPHEN | 1 | Oral | 0 | 1 | G | QID | ||||||||
| 126365471 | 12636547 | 11 | C | GAVISCON | ALUMINUM HYDROXIDEMAGNESIUM CARBONATE | 1 | Oral | 0 | 2 | DF | QD | ||||||||
| 126365471 | 12636547 | 12 | C | LASILIX | FUROSEMIDE | 1 | Oral | 0 | 20 | MEQ | TID | ||||||||
| 126365471 | 12636547 | 13 | C | LERCAN | LERCANIDIPINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126365471 | 12636547 | 2 | Acute myeloid leukaemia |
| 126365471 | 12636547 | 6 | Anal abscess |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126365471 | 12636547 | HO |
| 126365471 | 12636547 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126365471 | 12636547 | Anaphylactic reaction | |
| 126365471 | 12636547 | Atrial fibrillation | |
| 126365471 | 12636547 | Circulatory collapse | |
| 126365471 | 12636547 | Eyelid oedema | |
| 126365471 | 12636547 | Febrile bone marrow aplasia | |
| 126365471 | 12636547 | Pneumonitis | |
| 126365471 | 12636547 | Pruritus | |
| 126365471 | 12636547 | Urticaria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126365471 | 12636547 | 1 | 20160521 | 0 | ||
| 126365471 | 12636547 | 2 | 20160519 | 0 | ||
| 126365471 | 12636547 | 3 | 20160521 | 0 | ||
| 126365471 | 12636547 | 4 | 20160521 | 0 | ||
| 126365471 | 12636547 | 5 | 20160521 | 0 |